Karen Andersen, CFA

Title Collection Author Date
Novo Nordisk: CEO’s Surprise Departure Points to Challenging Obesity Market Dynamics Stock Insight Karen Andersen, CFA 19-05-25
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment Stock Insight Karen Andersen, CFA 20-12-24
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy Stock Insight Karen Andersen, CFA 05-06-24
Undervalued by 28%, This Stock Is a Buy for Patient Investors Stock Insight Karen Andersen, CFA 21-05-24
Omicron Variant Could Require Its Own Vaccine Stock Insight Karen Andersen, CFA 29-11-21
What Investors Should Know About the $26 Billion Opioid Settlement ESG Investing Karen Andersen, CFA 22-09-21
FDA Gives Full Approval to Pfizer COVID-19 Vaccine Stock Insight Karen Andersen, CFA 23-08-21
No Vaccine IP? No Problem! Stock Insight Karen Andersen, CFA 09-05-21
Vaccine Rollout, Herd Immunity to End Pandemic Market Insights Karen Andersen, CFA 12-01-21
Positive News From COVID-19 Vaccines Don't Change FVEs Stock Insight Karen Andersen, CFA 15-10-20
Coronavirus vaccine progress accelerates Market Insights Karen Andersen, CFA 14-05-20
Is Remdesivir-maker Gilead Sciences a 'buy'? Stock Insight Karen Andersen, CFA 11-05-20
U.S. coronavirus update: shutdown relaxes in H2, pipeline advances Market Insights Karen Andersen, CFA 02-04-20
Path to a vaccine emerges as investors overreact Market Insights Karen Andersen, CFA 20-03-20
Will Coronavirus trigger a global recession? Market Insights Karen Andersen, CFA 10-03-20
Two undervalued firms positioned to tackle liver disease Stock Insight Karen Andersen, CFA 19-09-18
Page   1 of 1
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility